June 02, 2014
Mylan Pharmaceuticals Inc. has reached a deal with Pfizer Inc. to allow it to begin selling generic versions of arthritis drug Celebrex by the end of the year, Mylan said in a statement Monday.
May 30, 2014
Teva Pharmaceutical Industries Ltd. has kept exclusive rights to market its generic version of Pfizer Inc.'s arthritis drug Celebrex, as a West Virginia federal judge ruled Thursday that the U.S. Food and Drug Administration didn't overstep its bounds in denying an exclusivity share to other generic-drug makers.
April 28, 2014
Watson Laboratories Inc. and Mylan Pharmaceuticals Inc. hit the U.S. Food and Drug Administration with separate lawsuits Monday after the regulator determined another generic-drug maker still has exclusivity rights to market its version of Pfizer Inc.'s arthritis drug Celebrex.